Prostate cancer brain metastases: Monitoring response to treatment with PSMA PET/CT

Anas Al-Zubaidi, Samuel Bezold, Peeyush Bhargava, Javier Villanueva-Meyer

Research output: Contribution to journalArticlepeer-review


Prostate cancer brain metastases are rare but increasingly recognized with prostate-specific membrane antigen (PSMA) PET/CT. Distinguishing tumor response from postradiation changes are challenging on MRI. PSMA PET/CT may clarify equivocal brain lesions after radiotherapy. A 71-year-old man with metastatic prostate cancer developed 2 new brain lesions on PSMA PET/CT. Lesions were high PSMA-avid and MRI follow up showed enhancing masses with edema, consistent with metastases. He underwent whole-brain radiation. Follow-up PSMA PET/CT after radiotherapy demonstrated significantly decreased lesion size and activity, with activity lower than blood pool, indicating a treatment response. MRI also showed near-resolution of the lesions. This case highlights the potential utility of PSMA PET/CT for detecting prostate cancer brain metastases and monitoring treatment response. PSMA PET/CT provides valuable complementary information to MRI for managing irradiated prostate cancer brain metastases.

Original languageEnglish (US)
Pages (from-to)2367-2370
Number of pages4
JournalRadiology Case Reports
Issue number6
StatePublished - Jun 2024
Externally publishedYes


  • Brain metastasis
  • Prostate cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Prostate cancer brain metastases: Monitoring response to treatment with PSMA PET/CT'. Together they form a unique fingerprint.

Cite this